European Medicines Agency (EMA)

Bluetongue vaccines

Two new vaccines against bluetongue disease in sheep and cattle

Vaccines will reduce animal suffering and economic losses

Read news on vaccines

Image showing pills and a magnifying glass

Safety committee meeting: January 2025 highlights

Investigation of risk of rare eye condition with semaglutide medicines

Read highlights

Nurse seen helping an elderly person hold a dandelion

Human medicines in 2024

114 medicines recommended for authorisation, 46 had a new active substance

Read 2024 overview

Rules on competing interests

Revised rules on handling competing interests

Updated policies for committee members, experts and Management Board members effective from May 2025

Read revised rules

Two female figures discussing, with the EU flag visible in the background

New EU rules for health technology assessments become effective

Faster and wider access to innovative health

Read about new rules

Find medicine

Find information on centrally authorised medicines

What's new

Find all new and updated information published on our website in one place

FAQs

Find answers to the most frequent asked questions we receive

Latest news

Blue tongue disease

Two new vaccines against bluetongue recommended for approval

These vaccines will protect sheep and cattle from disease outbreaks of newly emerged serotype-3

17 January 2025

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-15 January 2025

Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting

17 January 2025

Image showing pills and a magnifying glass

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

Investigation of risk of rare eye condition with semaglutide medicines

17 January 2025

Nurse seen helping an elderly person pick up and hold a dandelion

Human medicines in 2024

114 new medicines recommended for approval; 46 had a new active substance

16 January 2025

Handling conflict of interests

Revised rules on handling of competing interests published

Updated policies for committee members, experts and Management Board members effective from May 2025

14 January 2025

Two female figures discussing, with the EU flag visible in the background

New EU rules for health technology assessments become effective

Enhanced EU collaboration to allow faster and wider access to innovative health technologies

10 January 2025

Events

20 Jan2025

Committee for Herbal Medicinal Products (HMPC): 20-22 January 2025

European Medicines Agency, Amsterdam, the Netherlands

Start date: 20 January 2025

End date: 22 January 2025

21 Jan2025

Committee for Orphan Medicinal Products (COMP): 21-23 January 2025

European Medicines Agency, Amsterdam, the Netherlands

Start date: 21 January 2025

End date: 23 January 2025

22 Jan2025

Committee for Advanced Therapies (CAT): 22-24 January 2025

European Medicines Agency, Amsterdam, the Netherlands

Start date: 22 January 2025

End date: 24 January 2025

22 Jan2025

SPOR Status Update

Online

European Medicines Agency, Amsterdam, the Netherlands

Live broadcast

Start date: 22 January 2025, 10:00 (CET)

End date: 22 January 2025, 12:30 (CET)

27 Jan2025

Committee for Medicinal Products for Human Use (CHMP): 27-30 January 2025

European Medicines Agency, Amsterdam, the Netherlands

Start date: 27 January 2025

End date: 30 January 2025

27 Jan2025

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system

EudraVigilance is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of...

Online

Start date: 27 January 2025

End date: 31 January 2025